Chronic kidney disease (CKD)-associated osteoporosis is highly prevalent and increases the risk of fractures. Current therapy aims to preserve normal bone turnover, by maintaining parathyroid hormone (PTH) at relatively adequate levels. However, these patients continue to experience fractures.
Kidney International published a clinical update in Research Highlights on 20 Jan 2026.
The item focuses on Uremia and parathyroid hormone have distinct effects on bone protein and gene expression.
Review the original article for the full source wording and details.